State Street Corp Tyra Biosciences, Inc. Transaction History

State Street Corp

$2.25 Trillion
Q2 2024

A detailed history of State Street Corp transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, State Street Corp holds 368,484 shares of TYRA stock, worth $8.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

368,484

Previous 292,234 26.09%

Holding current value

$8.12 Million

Previous $4.79 Million 22.95%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$14.45 - $20.22 $1.1 Million - $1.54 Million	76,250 Added 26.09%	368,484 $5.89 Million
Q1 2024 May 15, 2024	BUY	$11.61 - $20.0 $312,076 - $537,600	26,880 Added 10.13%	292,234 $4.79 Million
Q4 2023 Feb 14, 2024	BUY	$11.01 - $14.95 $64,914 - $88,145	5,896 Added 2.27%	265,354 $3.68 Million
Q3 2023 Nov 14, 2023	BUY	$13.15 - $16.08 $40,515 - $49,542	3,081 Added 1.2%	259,458 $3.57 Million
Q2 2023 Aug 14, 2023	BUY	$11.99 - $17.51 $291,213 - $425,282	24,288 Added 10.46%	256,377 $4.37 Million
Q1 2023 May 15, 2023	BUY	$6.85 - $16.22 $105,921 - $250,809	15,463 Added 7.14%	232,089 $3.73 Million
Q4 2022 Feb 14, 2023	SELL	$5.68 - $8.81 $7,736 - $11,999	-1,362 Reduced 0.62%	216,626 $1.65 Million
Q3 2022 Nov 15, 2022	BUY	$6.61 - $12.42 $26,195 - $49,220	3,963 Added 1.85%	217,988 $1.92 Million
Q2 2022 Aug 15, 2022	BUY	$5.26 - $11.19 $54,414 - $115,760	10,345 Added 5.08%	214,025 $1.53 Million
Q1 2022 May 16, 2022	BUY	$10.03 - $14.09 $728,880 - $1.02 Million	72,670 Added 55.47%	203,680 $2.18 Million
Q4 2021 Feb 14, 2022	BUY	$12.23 - $31.35 $1.6 Million - $4.11 Million	131,010 New	131,010 $1.84 Million

Others Institutions Holding TYRA

# of Institutions

Shares Held

43.4M

Call Options Held

Put Options Held

View Full List

About Tyra Biosciences, Inc.

Ticker TYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,973,600
Market Cap $925M
Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...

More about TYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Tyra Biosciences, Inc. Transaction History